ADPT Adaptive Biotechnologies Corp
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1478320 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.9%
TTM net income YoY11.4%
TTM EPS YoY13.5%
Revenue 3-yr CAGR18.4%
Net income 3-yr CAGR—
Margins
Gross margin74.2%
Operating margin-16.2%
Net margin-23.7%
FCF margin-3.0%
EBITDA margin-11.6%
Returns
ROE-37.1%
ROA-12.0%
ROIC (approx.)-19.9%
Asset turnover0.51x
Leverage & solvency
Liabilities / assets73.1%
Debt / equity0.00x
Current ratio3.97x
Interest coverage-5.33x
Cash quality & payout
Operating cash flow / net income0.06x
Accruals ratio-11.3%
Payout ratio—
Capex / revenue1.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $276.98M | $178.96M |
| Cost of revenue | $71.36M | $72.08M |
| Gross profit | $205.62M | $106.88M |
| R&D expense | $93.77M | $102.95M |
| SG&A expense | $72.70M | $72.81M |
| Operating income | -$57.12M | -$162.55M |
| Interest expense | $11.78M | $11.58M |
| Pretax income | -$59.46M | -$159.59M |
| Income tax | $0 | $0 |
| Net income | -$59.50M | -$159.49M |
| EBITDA | -$41.12M | -$145.11M |
| EPS (basic) | -0.39 | -1.08 |
| EPS (diluted) | -0.39 | -1.08 |
| Weighted avg. shares (diluted) | 151.72M | 147.10M |
| Balance sheet | ||
| Cash & equivalents | $70.50M | $47.92M |
| Short-term investments | $156.49M | $174.37M |
| Receivables | $50.37M | $41.73M |
| Inventory | $9.82M | $8.44M |
| Current assets | $300.19M | $283.75M |
| PP&E, net | $34.11M | $48.62M |
| Goodwill | $118.97M | $118.97M |
| Intangibles | $1.73M | $3.42M |
| Total assets | $512.74M | $539.38M |
| Current liabilities | $89.92M | $98.05M |
| Short-term debt | $4.64M | $865,000 |
| Long-term debt | $126.57M | $132.41M |
| Total debt | $131.21M | $133.28M |
| Total liabilities | $287.74M | $336.89M |
| Shareholders' equity | $218.79M | $202.71M |
| Net debt | $60.71M | $85.36M |
| Shares outstanding | 153.78M | 147.77M |
| Cash flow statement | ||
| Operating cash flow | -$45.99M | -$95.21M |
| Capital expenditure | $2.96M | $3.66M |
| Free cash flow | -$48.95M | -$98.88M |
| Investing cash flow | $37.95M | $77.79M |
| Financing cash flow | $30.40M | $241,000 |
| Depreciation & amortization | $16.00M | $17.44M |
| Stock-based compensation | $51.48M | $53.61M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.